IPCI.TO - Intellipharmaceutics International Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.1950
0.0000 (0.00%)
As of 12:01PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.1950
Open0.1950
Bid0.1900 x 0
Ask0.1950 x 0
Day's Range0.1850 - 0.1950
52 Week Range0.1200 - 0.8200
Volume17,208
Avg. Volume32,200
Market Cap4.307M
Beta (3Y Monthly)3.00
PE Ratio (TTM)N/A
EPS (TTM)-0.5910
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • ACCESSWIRE

    Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi

    TORONTO, ON / ACCESSWIRE / November 18, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company") and Drs. Isa and Amina Odidi announce that, following the close of markets on November 15, 2019, the Company issued to Drs. Isa and Amina Odidi, by way of private placement, an unsecured convertible debenture of the Company in consideration for, and in the aggregate principal amount of, USD$250,000 (the "Debenture"). The principal amount owing under the Debenture is convertible at any time and from time to time into common shares in the capital of the Company (the "Common Shares") at a conversion price equal to USD$0.12 per Common Share.

  • ACCESSWIRE

    Intellipharmaceutics Announces Settlement Agreement in Class Action Lawsuit, Which is Subject to Court Approval

    The settlement is subject to the approval of the court following notice to class members. The stipulation of settlement provides for a settlement payment of US$1.6 million, which Intellipharmaceutics anticipates will be funded by available insurance.

  • CNW Group

    IIROC Trade Resumption - IPCI

    IIROC Trade Resumption - IPCI

  • ACCESSWIRE

    Intellipharmaceutics Update on its Oxycodone ER New Drug Application

    TORONTO, ON / ACCESSWIRE / October 24, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has been advised by the U.S. Food and Drug Administration ("FDA") that product specific advisory committee meetings for opioid analgesics, as related to Intellipharmaceutics' Oxycodone ER New Drug Application ("NDA"), which were previously postponed, as announced on July 24, 2019, are no longer on hold. The Company is pleased with this development and is prepared to attend any advisory committee meetings in the future.

  • CNW Group

    IIROC Trading Halt - IPCI

    IIROC Trading Halt - IPCI

  • ACCESSWIRE

    Intellipharmaceutics Announces Third Quarter 2019 Results

    TORONTO, ON / ACCESSWIRE / October 11, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE

    Intellipharmaceutics Announces an Update in the Purdue Litigation

    TORONTO, ONTARIO / ACCESSWIRE / October 4, 2019 / Intellipharmaceutics International Inc. (IPCIF)(IPCI.TO) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that following the filing of a bankruptcy stay by Purdue Pharma L.P., the Company's ongoing litigation cases, number 1:17-cv-00392-RGA and 1:18-cv-00404-RGA-SRF between Purdue Pharma L.P. et al and Intellipharmaceutics, have been stayed and the existing trial dates in both cases have been vacated by orders issued in each case by the judge in the District of Delaware on October 3, 2019. The Company and its management intend to continue to vigorously defend against the claims of patent infringement made by Purdue Pharma L.P. in the above cases.

  • ACCESSWIRE

    Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.

    TORONTO, ON / ACCESSWIRE / September 5, 2019 / Intellipharmaceutics International Inc. (IPCIF) and (IPCI.TO) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and commercial supply agreement with Tris Pharma, Inc. ("Tris"), by which the Company has granted Tris an exclusive license to market, sell and distribute in the United States, Desvenlafaxine Succinate ER in the 50 and 100 mg strengths (the "licensed products") approved for sale in the U.S. market by the U.S. Food and Drug Administration ("FDA"). Several other generic versions of the licensed products are currently available in the market.

  • ACCESSWIRE

    Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.

    TORONTO, ON / ACCESSWIRE / August 15, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and commercial supply agreement with Tris Pharma, Inc. ("Tris"), by which the Company has granted Tris an exclusive license to market, sell and distribute in the United States, Quetiapine ER in the 50, 150, 200, 300 and 400 mg strengths (the "licensed products") approved for sale in the US market by the U.S. Food and Drug Administration ("FDA"). Several other generic versions of the licensed products are currently available in the market.

  • ACCESSWIRE

    Intellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug Application

    TORONTO, ON / ACCESSWIRE / July 24, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company,") a pharmaceutical company specializing ...

  • ACCESSWIRE

    Intellipharmaceutics Announces Second Quarter 2019 Results

    TORONTO, ON / ACCESSWIRE / July 10, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, ...

  • ACCESSWIRE

    Intellipharmaceutics International Inc. Announces $10,000,000 Equity Financing Commitment

    TORONTO, ON / ACCESSWIRE / July 8, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has obtained an equity financing commitment of up to $10,000,000 from Silverback Capital Corporation, a private investment firm ("Silverback Capital"). During the 36-month term of the equity financing commitment, Intellipharmaceutics may sell shares of its common stock to Silverback Capital up to the $10,000,000 total commitment at a 25% discount to the volume weighted average price of the Company’s common stock for the 5 trading days prior to the date the Company provides notice to Silverback Capital, or if the maximum discount rate allowed by the Company’s principal exchange is less than 25%, then the maximum discount rate allowed.

  • ACCESSWIRE

    Intellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada

    TORONTO, ON / ACCESSWIRE / May 30, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company's pre-existing license to conduct activities with Cannabidiol ("CBD") has been migrated by Health Canada to a Cannabis Drug License ("CDL") under the Cannabis Regulations. Intellipharmaceutics' new CDL allows the Company to continue to possess cannabis, produce a drug containing cannabis and sell a drug containing cannabis in Canada.

  • ACCESSWIRE

    Intellipharmaceutics Reports Director Election Results

    TORONTO, ON / ACCESSWIRE / May 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE

    Intellipharmaceutics to present at the 9th Annual LD Micro Invitational

    TORONTO, ON / ACCESSWIRE / May 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it will be presenting at the 9th annual LD Micro Invitational on Tuesday June 4th, 2019 at 2:20pm PST. Executive Greg Powell, CFO will be presenting and meeting with investors. Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

  • ACCESSWIRE

    Intellipharmaceutics Announces FDA Approval for Generic Pristiq(R)

    TORONTO, ON / ACCESSWIRE / May 10, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for desvenlafaxine extended-release tablets in the 50 and 100 mg strengths. The approved product is a generic equivalent of the branded product Pristiq®.

  • ACCESSWIRE

    Intellipharmaceutics Closes US$1.05 Million Convertible Debenture Financing with Drs. Isa and Amina Odidi

    TORONTO, ON / ACCESSWIRE / May 7, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company") and Drs. Isa and Amina Odidi announce that, following the close of markets on May 1, 2019, the Company issued to Drs. Isa and Amina Odidi, by way of private placement, an unsecured convertible debenture of the Company in consideration for, and in the aggregate principal amount of, USD$1,050,000 (the "Debenture"). The principal amount owing under the Debenture is convertible at any time and from time to time into common shares in the capital of the Company (the "Common Shares") at a conversion price equal to USD$0.59 per Common Share.

  • ACCESSWIRE

    Intellipharmaceutics Announces First Quarter 2019 Results

    TORONTO, ON / ACCESSWIRE / April 15, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in ...

  • ACCESSWIRE

    U.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review

    TORONTO, ON / ACCESSWIRE / March 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE

    Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System

    TORONTO, ON / ACCESSWIRE / March 19, 2019 / Intellipharmaceutics International Inc. (Nasdaq and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced that today the Company received formal notice that the Nasdaq Hearings Panel had determined to delist the Company's shares from The Nasdaq Stock Market LLC ("Nasdaq") based upon the Company's non-compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). The suspension of trading on Nasdaq will take effect with the open of business on Thursday, March 21, 2019.

  • ACCESSWIRE

    Intellipharmaceutics Announces Fiscal Year 2018 Results

    TORONTO, ON / ACCESSWIRE / February 22, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in ...

  • ACCESSWIRE

    Intellipharmaceutics Announces FDA Tentative Approval of Generic Pristiq(R)

    TORONTO, ON / ACCESSWIRE / February 20, 2019 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for desvenlafaxine extended-release tablets in the 50 and 100 mg strengths. The approved product is a generic equivalent of the branded product Pristiq® sold in the U.S. by Wyeth Pharmaceuticals, LLC ("Wyeth"). The Company previously announced that it had entered into a license and commercial supply agreement with Mallinckrodt LLC ("Mallinckrodt"), which granted Mallinckrodt, subject to its terms, an exclusive license to market, sell and distribute in the U.S. the Company's desvenlafaxine extended-release tablets (generic Pristiq®).